The National Bone and Joint Decade, 2002-2011, envisions a series of initiatives among physicians, health professionals, patients, and communities, working together to promote research and development into therapies, preventative measures, and cures for the rheumatic diseases. This comes at a time when there is a growing concern that the number of newly trained academic scientists equipped to make major advances and to assume leadership roles will be inadequate. Accordingly, the Fellowship Training Program in Rheumatology and Clinical Immunogenetics represents a cooperative effort of accomplished faculty from the academic components of the University of Texas Health Science Center at Houston and the Texas Children's Hospital to provide to outstanding, academically pre-and postdoctoral fellows intensive basic or clinical research training in rheumatology, genetics and health services research. A productive and collaborative group of senior scientists and physician-scientists with complementary interests and a demonstrated commitment to mentorship and training will serve as mentoring faculty to two predoctoral and four postdoctoral fellows. The faculty laboratories offer research experience in important areas of rheumatology, genetics and molecular biology. The program provides training and didactic instruction in fundamental and state-of-the-art disciplines, including molecular genetics, biochemistry, transgenic technologies, immunology, genomics and epidemiology. The trainees will also profit from the substantial resources of the Texas Medical Center and the enormous population of at-risk or affected patients in the area. All applicants in this program must have a firm commitment to a career in academic investigation and to the goals of the Training Program. All trainees will be required to attend specific courses addressing research methodology, experimental design, research integrity and ethics, and representation by trainees from diverse backgrounds will be encouraged. Thus this Program will contribute to a new generation of academic rheumatologists equipped to address challenging problems in rheumatology, genetics and health services research.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Institutional National Research Service Award (T32)
Project #
5T32AR052283-04
Application #
7880189
Study Section
Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee (AMS)
Program Officer
Mao, Su-Yau
Project Start
2007-07-01
Project End
2012-06-30
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
4
Fiscal Year
2010
Total Cost
$235,701
Indirect Cost
Name
University of Texas Health Science Center Houston
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800771594
City
Houston
State
TX
Country
United States
Zip Code
77225
Wu, Minghua; Pedroza, Mesias; Lafyatis, Robert et al. (2014) Identification of cadherin 11 as a mediator of dermal fibrosis and possible role in systemic sclerosis. Arthritis Rheumatol 66:1010-21
Liu, Xiaochun; Mayes, Maureen D; Pedroza, Claudia et al. (2013) Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis? Arthritis Care Res (Hoboken) 65:1375-80
Elhaj, Mona; Charles, Julio; Pedroza, Claudia et al. (2013) Can serum surfactant protein D or CC-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis? J Rheumatol 40:1114-20
Murthy, Vijaya; Willis, Rohan; Romay-Penabad, Zurina et al. (2013) Value of isolated IgA anti-?2 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome. Arthritis Rheum 65:3186-93
Liu, Xiaochun; Mayes, Maureen D; Tan, Filemon K et al. (2013) Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis. Arthritis Rheum 65:226-35
Schneider, Daniel J; Wu, Minghua; Le, Thuy T et al. (2012) Cadherin-11 contributes to pulmonary fibrosis: potential role in TGF-? production and epithelial to mesenchymal transition. FASEB J 26:503-12
Willis, R; Seif, A M; McGwin Jr, G et al. (2012) Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort. Lupus 21:830-5
Wu, Minghua; Schneider, Daniel J; Mayes, Maureen D et al. (2012) Osteopontin in systemic sclerosis and its role in dermal fibrosis. J Invest Dermatol 132:1605-14
Sharif, Roozbeh; Mayes, Maureen D; Tan, Filemon K et al. (2012) IRF5 polymorphism predicts prognosis in patients with systemic sclerosis. Ann Rheum Dis 71:1197-202
Sharif, Roozbeh; Fritzler, Marvin J; Mayes, Maureen D et al. (2011) Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysis. J Rheumatol 38:1622-30

Showing the most recent 10 out of 12 publications